A Short 5′triphosphate RNA nCoV-L Induces a Broad-Spectrum Antiviral Response by Activating RIG-I

Ziyang Song, Qian Wang, Lianlian Bian, Chaoqiang An, Bopei Cui, Qunying Mao, Desheng Wu, Qian He, Yu Bai, Jianyang Liu, Lifang Song, Dong Liu, Jialu Zhang, Fan Gao, Xiuling Li, Zhenglun LiangViruses 2022 · DOI

TL;DR

Researchers have developed a novel short RNA molecule, nCoV-L, that effectively triggers the innate immune system's RIG-I pathway. This activation leads to a broad-spectrum antiviral response, demonstrating significant protection against multiple RNA viruses, including SARS-CoV-2, in both cell cultures and animal models.

What Problem Does This Paper Address?

The paper addresses the critical need for effective and broad-spectrum antiviral therapies. Current treatments often target specific viruses, limiting their utility against emerging or diverse viral threats. The authors explore the potential of activating the innate immune system, specifically the RIG-I pathway, as a universal defense mechanism against viral infections. RIG-I is a key pattern recognition receptor that detects viral RNA, initiating an antiviral cascade. However, designing specific RNA molecules that can reliably and potently activate RIG-I for therapeutic purposes remains a challenge. This study aims to design and evaluate such a molecule, nCoV-L, for its ability to induce a robust antiviral response against a range of RNA viruses.

Methods

The researchers designed a short RNA molecule, nCoV-L, incorporating a 5' triphosphate (5'PPP) and a double-stranded stem-loop structure, features known to be recognized by RIG-I.

  • In vitro studies:
    • RIG-I activation assays: They used HEK293 cell lines with a luciferase reporter gene under the control of an interferon-stimulated gene (ISG54) promoter. These cell lines were genetically modified to knock out specific pattern recognition receptors (RIG-I, MDA5, TLR3, TLR7, TLR8) to pinpoint nCoV-L's target. Transfection with nCoV-L and subsequent luciferase activity measurement revealed nCoV-L's specific activation of RIG-I.
  • Western blotting: This technique was used to detect the expression and phosphorylation of key proteins in the RIG-I signaling pathway, such as IRF3 and ISG56, following nCoV-L treatment.
  • RT-qPCR: This method quantified the expression levels of interferon-beta (IFN-β) mRNA, a crucial antiviral cytokine, after nCoV-L treatment.
  • Viral inhibition assays: Cell cultures were infected with various RNA viruses (Enterovirus 71, Coxsackievirus B5, Poliovirus 1, and Influenza A virus) after treatment with nCoV-L. Viral loads were then assessed using RT-qPCR and viral titers in supernatants were measured to evaluate nCoV-L's antiviral efficacy.
  • In vivo studies:
    • Mouse models: Two mouse models were used:
  • Suckling BALB/c mice: These were used to assess nCoV-L's protective effect against a lethal dose of Enterovirus 71 (EV71).
  • K18-hACE2 transgenic mice: These mice were used to evaluate nCoV-L's prophylactic and therapeutic effects against a lethal dose of SARS-CoV-2.
  • Viral load and IFN-β measurement: In the EV71 model, viral loads in various tissues and IFN-β levels in serum were measured.
  • Histopathological analysis: Lung tissues from SARS-CoV-2 infected mice were examined to assess the severity of viral-induced pathology.
  • Survival and weight monitoring: Survival rates and weight changes were closely monitored in both animal models.

Datasets

Not discussed in the paper. The study primarily relies on experimental data generated from cell cultures and animal models.

Key Insights and Ideas

  • Targeted RIG-I Activation: The design of nCoV-L, with its specific 5'PPP and stem-loop structure, successfully targets and activates the RIG-I receptor, bypassing other pattern recognition receptors. This specificity is crucial for a predictable and potent immune response.
  • Broad-Spectrum Efficacy: nCoV-L demonstrates effectiveness against a diverse range of RNA viruses, including enteroviruses, poliovirus, influenza, and importantly, SARS-CoV-2. This suggests a potential for a single therapeutic agent to combat multiple viral threats.
  • Innate Immunity as a Defense: The study highlights the power of harnessing the body's innate immune system. By activating RIG-I, nCoV-L triggers a cascade of antiviral responses, including interferon production, which is a fundamental defense mechanism against viruses.
  • Prophylactic Advantage: The prophylactic administration of nCoV-L showed a more pronounced protective effect, particularly against SARS-CoV-2, suggesting that pre-activating the immune system can be a highly effective strategy for preventing or mitigating severe disease.
  • Potential for Future Antivirals: The findings position nCoV-L as a promising candidate for developing a new class of broad-spectrum antiviral drugs, offering a much-needed alternative to virus-specific therapies.

Key Results

  • In vitro: nCoV-L specifically activated RIG-I in HEK293 cells, leading to the induction of IFN-β and ISG56. It significantly inhibited the replication of EV-71, CV-B5, PV-1, and IAV in cell cultures, with efficacy often surpassing that of a control RNA agonist (M8).
  • In vivo (EV71): In suckling mice, a 10 µg dose of nCoV-L administered 1 hour after lethal EV71 infection completely prevented mortality and significantly reduced viral loads in various tissues. It also induced higher IFN-β levels compared to control groups.
  • In vivo (SARS-CoV-2): Prophylactic administration of nCoV-L (30 µg) 6 hours before SARS-CoV-2 infection in K18-hACE2 mice dramatically reduced mortality (1 out of 5 mice died vs. all control mice dying) and mitigated morbidity symptoms. Therapeutic administration (0.5 hours post-infection) also showed some protective effects. Histopathological analysis of lung tissue in prophylactically treated mice revealed milder lesions.

Limitations and Future Work

  • Omicron Strain Potential: The authors suggest that nCoV-L might be even more effective against the Omicron variant of SARS-CoV-2, as this variant has mutations that may lead to weaker inhibition of IFN signaling compared to the Delta variant. This warrants further investigation.
  • DNA Virus Efficacy: The study focused on RNA viruses. The authors mention that the role of RIG-I agonists against DNA viruses has been less explored and suggests this as an area for future research.
  • Administration Timing: While prophylactic administration showed better results, the study also explored therapeutic administration. Further optimization of the timing and dosage for therapeutic use could be beneficial.
  • Mechanism of Action in Complex Systems: While the study elucidates RIG-I activation and downstream signaling, further research could explore the broader immunological impact and potential off-target effects in more complex in vivo settings.
  • Clinical Translation: The findings are promising, but extensive preclinical and clinical trials would be necessary to establish the safety and efficacy of nCoV-L in humans.

Summary updated

Abstract

Small molecular nucleic acid drugs produce antiviral effects by activating pattern recognition receptors (PRRs). In this study, a small molecular nucleotide containing 5'triphosphoric acid (5'PPP) and possessing a double-stranded structure was designed and named nCoV-L. nCoV-L was found to specifically activate RIG-I, induce interferon responses, and inhibit duplication of four RNA viruses (Human enterovirus 71, Human poliovirus 1, Huma<i>n</i> coxsackievirus B5 and Influenza A virus) in cells. In vivo, nCoV-L quickly induced interferon responses and protected BALB/c suckling mice from a lethal dose of the enterovirus 71. Additionally, prophylactic administration of nCoV-L was found to reduce mouse death and relieve morbidity symptoms in a K18-hACE2 mouse lethal model of SARS-CoV-2. In summary, these findings indicate that nCoV-L activates RIG-I and quickly induces effective antiviral signals. Thus, it has potential as a broad-spectrum antiviral drug.
BibTeX
@inproceedings{song2022short,
  author = {Ziyang Song and Qian Wang and Lianlian Bian and Chaoqiang An and Bopei Cui and Qunying Mao and Desheng Wu and Qian He and Yu Bai and Jianyang Liu and Lifang Song and Dong Liu and Jialu Zhang and Fan Gao and Xiuling Li and Zhenglun Liang},
  title = {{A Short 5′triphosphate RNA nCoV-L Induces a Broad-Spectrum Antiviral Response by Activating RIG-I}},
  booktitle = {Viruses},
  year = {2022},
  doi = {10.3390/v14112451},
}
Figure